मूलभूत आँकड़े
| CIK | 1936258 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NewAmsterdam Pharma Company N.V. - Equity Warrant
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| September 2, 2025 |
Corporate Presentation September 2, 2025 Nasdaq: NAMS Corporate Presentation September 2, 2025 Nasdaq: NAMS Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. |
|
| September 2, 2025 |
FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September, 2 2025 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) |
|
| August 18, 2025 |
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib - Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia - - Ne |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) (C |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) (C |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q fafROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41562 NewAmsterdam Pharma Company N. |
|
| August 6, 2025 |
Employment Agreement, dated July 11, 2025, between NewAmsterdam Pharma B.V. and Dr. John Kastelein. Exhibit 10.2 EMPLOYMENT AGREEMENT 1. NewAmsterdam Pharma B.V., a company with limited liability organised under the laws of the Netherlands, having its corporate seat at Naarden, registered with the Chamber of Commerce under number 76133141, hereinafter referred to as the "Employer"; and 2. Mr Prof. J.J.P. (John) Kastelein, residing at [***], hereinafter referred to as the "Employee". The Employer |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) (Co |
|
| August 6, 2025 |
Form of Restricted Stock Unit Award Agreement AWARD AGREEMENT THIS AGREEMENT IS BETWEEN 1. NewAmsterdam Pharma Company N.V., a public company with limited liability, having its corporate seat in Naarden (address: Gooimeer 2-35 1411 DC Naarden, trade register number: 86649051) (the “Company”); and 2. [name] (the “Participant”). NOW HEREBY AGREE AS FOLLOWS 1.1.1 Capitalised terms used herein have the meanings ascribed thereto in the Company’s l |
|
| August 6, 2025 |
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – BROADWAY Alzheimer’s disease analysis presented at AAIC 2025 showed obicetrapib significantly reduced plasma p-tau217 levels versus placebo in both the full analysis set and in ApoE4 carriers, over 12 months, with favorable trends observed in additional Alzheimer’s biomarkers – – $783. |
|
| July 30, 2025 |
Obicetrapib in Alzheimer’s Disease (AD): First-in-Class Evidence from BROADWAY July 30, 2025 Obicetrapib in Alzheimer’s Disease (AD): First-in-Class Evidence from BROADWAY July 30, 2025 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. |
|
| July 30, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) (Com |
|
| July 30, 2025 |
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025 - Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0. |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Com |
|
| June 11, 2025 |
Welcome to R&D Day June 11, 2025 Welcome to R&D Day June 11, 2025 Disclaimer Forward Looking Statements Certain statements included in this presentation (together with oral statements made in connection herewith, this “Presentation”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. |
|
| June 11, 2025 |
FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) (Com |
|
| June 9, 2025 |
Exhibit 99.1 NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial — Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer’s disease biomarker in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215), supporting the em |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Comm |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Comm |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41562 NewAmsterdam Pharma Company N. |
|
| May 8, 2025 |
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results – EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – - BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively - - Company to host R&D day on June 11th, 2025 in New York City - –$808. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Commi |
|
| May 7, 2025 |
EX-99.1 Exhibit 99.1 NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – Phase 3 |
|
| April 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Co |
|
| April 17, 2025 |
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors Exhibit 99.1 NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors Naarden, the Netherlands and Miami, USA; April 17, 2025 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotei |
|
| March 10, 2025 |
Up to $250,000,000 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-285462 PROSPECTUS Up to $250,000,000 Ordinary Shares We previously entered into an amended and restated sales agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”), dated August 9, 2024, relating to the sale of our ordinary shares, nominal value of €0.12 per share (the “Ordinary Shares”), offered by this |
|
| March 6, 2025 |
NewAmsterdam Pharma Company N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands CORRESP NewAmsterdam Pharma Company N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands March 6, 2025 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3561 Attn: Jason Drory Re: NewAmsterdam Pharma Company N.V. Registration Statement on Form S-3 Filed February 28, 2025 File No. 333-285462 Ladies and Gentlemen: Pursuant to Rule 46 |
|
| February 28, 2025 |
Exhibit 4.2 NEWAMSTERDAM PHARMA COMPANY N.V. AS ISSUER, AND [], AS TRUSTEE, SUBORDINATED INDENTURE DATED AS OF [, ] SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE Reconciliation and tie between the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the Indenture dated as of [], []. SECTION OF Trust Indenture Act SECTION OF INDENTURE 310(a)(1) and (2) 7.09 310(a)(3) and (4 |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 28, 2025 |
Exhibit 4.1 NEWAMSTERDAM PHARMA COMPANY N.V. AS ISSUER, AND [], AS TRUSTEE, SENIOR INDENTURE DATED AS OF [, ] SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE Reconciliation and tie between the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the Indenture dated as of [], []. SECTION OF Trust Indenture Act SECTION OF INDENTURE 310(a)(1) and (2) 7.09 310(a)(3) and (4) Not applic |
|
| February 28, 2025 |
Consent of Covington & Burling LLP (included in Exhibit 5.3 to this Registration Statement). EX-5.3 Exhibit 5.3 February 28, 2025 NewAmsterdam Pharma Company N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands Ladies and Gentlemen: We have acted as United States counsel to NewAmsterdam Pharma Company N.V., a Dutch public limited liability company (naamloze vennootschap) (the “Company”), in connection with the registration by the Company under the Securities Act of 1933, as amended (the |
|
| February 28, 2025 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NewAmsterdam Pharma Company N. |
|
| February 26, 2025 |
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - EMA submission expected in 2H25 by partner Menarini - - Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 - - Phase 3 PREVAIL CVOT remains on track - - $834. |
|
| February 26, 2025 |
Contrat de mise à disposition de Travailleurs à titre principal (travail en régie) entre Main Employee placement contract between Globalization Partners Switzerland SA ("G-P") Globalization Partners Switzerland SA ("G-P") Route de Frontenex 86 bis, 1208 Genève, Suisse Route de Frontenex 86 bis, 1208 Genève, Switzerland L'employeur as Employer et and Juliette Berangere Audet [***] Juliette Berangere Audet [***] L'employé as Employee 1. |
|
| February 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) |
|
| February 26, 2025 |
Exhibit 4.4 DESCRIPTION OF OUR SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and warrants to purchase ordinary shares of NewAmsterdam Pharma Company N.V. (the “Company,” “we,” “us,” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also includes a description of the ma |
|
| February 26, 2025 |
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41562 NewAmsterdam Pharma Company N. |
|
| February 26, 2025 |
Insider Trading Policy of the Company 1 INSIDER TRADING POLICY NEWAMSTERDAM PHARMA COMPANY N.V. INTRODUCTION Article 1 This document sets out the Company's insider trading policy. DEFINITIONS AND INTERPRETATION Article 2 2.1 In this policy the following definitions shall apply: Article An article of this policy. Board The Company's board of directors. CEO The Company's chief executive officer. Chairperson The chairperson of the Board. |
|
| February 26, 2025 |
Letter Agreement, dated March 22, 2024, between NewAmsterdam Pharma Company N.V. and Juliette Audet. Juliette Audet Dear Juliette: In connection with (a) the assignment of your employment to NewAmsterdam Pharma B. |
|
| February 26, 2025 |
Douglas Kling [***] [***] Dear Doug: On behalf of NewAmsterdam Pharma Corporation, I am pleased to present you (“you” or “Executive”) this updated letter regarding your employment with the Company. |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedu |
|
| February 14, 2025 |
EXHIBIT A - JOINT FILING AGREEMENT EXHIBIT A - JOINT FILING AGREEMENT This joint filing agreement is made and entered into as of this 14th day of February, 2025, by and among Viking Global Investors LP, Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Opportunities Drawdown GP LLC, Viking Global Opportunities Drawdown Portfolio GP LLC, Viking Global Opportunities Drawdown (Aggregator) LP, O. |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) ( |
|
| January 10, 2025 |
Exhibit 99.1 NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities — Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner Menarini – — Data from Phase 2 VINCENT trial expected by 2H25, which explores effect of obicetrapib a |
|
| January 10, 2025 |
Exhibit 99.2 Corporate Presentation January 2025 Nasdaq: NAMS Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in whi |
|
| January 7, 2025 |
As filed with the Securities and Exchange Commission on January 7, 2025 As filed with the Securities and Exchange Commission on January 7, 2025 Registration No. |
|
| January 7, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) NewAmsterdam Pharma Company N. |
|
| December 17, 2024 |
SC 13D/A 1 d507124dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares (Title of Class of Securities) N62509 109 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Na |
|
| December 17, 2024 |
NAMS / NewAmsterdam Pharma Company N.V. / BCLS II Investco, LP - SC 13D/A Activist Investment SC 13D/A 1 d825364dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3) NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, nomina |
|
| December 17, 2024 |
SC 13D/A 1 d913199dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, Nominal value €0.12 per share (Title of Class of Securities) N62509 109 (CUSIP Number) Forbion Capital Partners Gooimeer 2-35 1411 DC Naarden The Ne |
|
| December 17, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.I 2 d825364dex99i.htm EX-99.I Exhibit I AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (incl |
|
| December 13, 2024 |
12,117,347 Ordinary Shares Pre-funded warrants to Purchase 4,882,653 Ordinary Shares Table of Contents File Pursuant to Rule 424(b)(5) Registration Nos. 333-280687 and 333-283740 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2024) 12,117,347 Ordinary Shares Pre-funded warrants to Purchase 4,882,653 Ordinary Shares We are offering 12,117,347 ordinary shares, with a nominal value of €0.12 per share (the “Ordinary Shares”) and, in lieu of Ordinary Shares to certain investors, p |
|
| December 13, 2024 |
EX-99.1 Exhibit 99.1 NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Naarden, the Netherlands and Miami, USA; December 10, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiov |
|
| December 13, 2024 |
EX-99.2 Exhibit 99.2 NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Naarden, the Netherlands and Miami, USA; December 11, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ca |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) |
|
| December 13, 2024 |
Exhibit 4.1 Form of Pre-Funded Warrant NEWAMSTERDAM PHARMA COMPANY N.V. WARRANT TO PURCHASE ORDINARY SHARES Number of Ordinary Shares: [] (subject to adjustment) Warrant No. [] Date of Issuance: December [], 2024 (such date, the “Original Issue Date”) NewAmsterdam Pharma Company N.V., a Dutch public limited liability company (the “Company”), hereby certifies that, for good and valuable considerati |
|
| December 13, 2024 |
Exhibit 1.1 NewAmsterdam Pharma Company N.V. 12,117,347 Ordinary Shares (Nominal Value €0.12 Per Share) And Pre-Funded Warrants to Purchase 4,882,653 Ordinary Shares UNDERWRITING AGREEMENT December 11, 2024 JEFFERIES LLC GOLDMAN SACHS & CO. LLC LEERINK PARTNERS LLC TD SECURITIES (USA) LLC GUGGENHEIM SECURITIES, LLC WILLIAM BLAIR & COMPANY, L.L.C. As Representatives of the several Underwriters c/o |
|
| December 11, 2024 |
As filed with the Securities and Exchange Commission on December 11, 2024 As filed with the Securities and Exchange Commission on December 11, 2024 Registration No. |
|
| December 11, 2024 |
Calculation of Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NewAmsterdam Pharma Company N. |
|
| December 10, 2024 |
Exhibit 99.1 NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia — Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically signifi |
|
| December 10, 2024 |
$300,000,000 Ordinary Shares Pre-funded warrants to Purchase Ordinary Shares 424B5 Table of Contents This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended, and the information in this preliminary prospectus supplement is not complete and may be changed. |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) |
|
| December 10, 2024 |
Exhibit 99.2 BROADWAY Topline Results December 10, 2024 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which suc |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) |
|
| November 20, 2024 |
Exhibit 99.2 TANDEM Topline Results November 20, 2024 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such |
|
| November 20, 2024 |
Exhibit 99.1 NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH — Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) |
|
| November 18, 2024 |
EX-99.1 Exhibit 99.1 NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 – Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% a |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) |
|
| November 15, 2024 |
EX-99.7 2 d863823dex997.htm EX-99.7 Exhibit 99.7 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersig |
|
| November 15, 2024 |
SC 13D/A 1 d863823dsc13da.htm SC 13D/A CUSIP No. N62509 109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, Nominal value €0.12 per share (Title of Class of Securities) N62509 109 (CUSIP Number) Forbion Capital Partners Gooimeer 2-35 1 |
|
| November 14, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2427451d11ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissi |
|
| November 14, 2024 |
NAMS / NewAmsterdam Pharma Company N.V. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d11sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* NEWAMSTERDAM PHARMA COMPANY N.V. (Name of Issuer) Ordinary Shares, Nominal value €0.12 per share (Title of Class of Securities) N62509 109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) ( |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41562 NewAmsterdam Pharma Company N. |
|
| November 6, 2024 |
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results – Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – – On-track to report topline data from pivotal Phase 3 BROADWAY trial in 4Q 2024 – – Strong balance sheet with $422. |
|
| October 28, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F/A for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the |
|
| October 28, 2024 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Davidson, M.D., certify that: 1. I have reviewed this annual report on Form 20-F/A of NewAmsterdam Pharma Company N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a materia |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| October 28, 2024 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian Somaiya, certify that: 1. I have reviewed this annual report on Form 20-F/A of NewAmsterdam Pharma Company N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or o |
|
| October 28, 2024 |
Description of Share Capital and Articles of Association. Exhibit 2.4 DESCRIPTION OF OUR SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and warrants to purchase ordinary shares of NewAmsterdam Pharma Company N.V. (the “Company,” “we,” “us,” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also includes a description of the ma |
|
| October 28, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F/A for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the |
|
| October 18, 2024 |
October 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Frank Wyman and Angela Connell Re: NewAmsterdam Pharma Company N.V. Form 10-K for the Year Ended December 31, 2023 (the “Form 10-K”) Filed February 28, 2024 File No. 001-41562 Dear Mr. Wyman and Ms. Connell, NewAmsterdam Pha |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) ( |
|
| August 23, 2024 |
NAMS / NewAmsterdam Pharma Company N.V. / AMGEN INC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, nominal value EUR 0.12 per share (Title of Class of Securities) N62509109 (CUSIP Number) August 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| August 23, 2024 |
EX-99.1 2 d856951dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the com |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
Up to $150,000,000 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-280687 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2024) Up to $150,000,000 Ordinary Shares We have entered into an amended and restated sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) and TD Securities (USA) LLC (“TD Cowen”), an affiliate of Cowen, dated August 9, 2024, relating to the sa |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Co |
|
| August 9, 2024 |
Exhibit 1.1 Execution Version NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES AMENDED AND RESTATED SALES AGREEMENT August 9, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, NY 10017 Ladies and Gentlemen: NewAmsterdam Pharma Company N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Company”), and Cowen and Company, LLC |
|
| August 8, 2024 |
August 8, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Frank Wyman and Angela Connell Re: NewAmsterdam Pharma Company N.V. Form 10-K for the Year Ended December 31, 2023 (the “Form 10-K”) Filed February 28, 2024 File No. 001-41562 Dear Mr. Wyman and Ms. Connell, NewAmsterdam Pharm |
|
| August 7, 2024 |
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH; achieved primary endpoint of LS mean reduction in LDL-C versus placebo, as well as statistically significant reductions in other biomarkers, with safety results comparable to placebo – - Extended US IP protection into 2043 with a new composition of matter patent - - On-track to report topline data from pivotal Phase 3 BROADWAY trial in 4Q 2024 – - Completed enrollment of pivotal Phase 3 TANDEM trial evaluating fixed-dose combination of obicetrapib and ezetimibe; topline data expected in 1Q 2025 - - Strong financial position; $430. |
|
| August 7, 2024 |
NewAmsterdam Pharma Company N.V. Inducement Plan INDUCEMENT PLAN NEWAMSTERDAM PHARMA COMPANY N.V. INTRODUCTION Article 1 1.1 This document sets out the Company’s inducement plan for prospective Employees who qualify as Eligible Participants. This Plan applies in addition, and without prejudice, to the Company’s long-term incentive plan, the Company’s supplementary long-term incentive plan and the Company’s roll-over option plan; the same applies |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41562 NewAmsterdam Pharma Company N. |
|
| August 7, 2024 |
Form of Option Award agreement under the Inducement Plan 1 AWARD AGREEMENT THIS AGREEMENT IS BETWEEN 1. NewAmsterdam Pharma Company N.V., a public company with limited liability, having its corporate seat in Naarden (address: Gooimeer 2-35 1411 DC Naarden, trade register number: 86649051) (the “Company”); and 2. [name] (the “Participant”). NOW HEREBY AGREE AS FOLLOWS 1.1 Capitalised terms used herein have the meanings ascribed thereto in the Company’s i |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) (Co |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Com |
|
| July 29, 2024 |
EX-99.2 BROOKLYN Topline Results July 2024 Nasdaq: NAMS Exhibit 99.2 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions |
|
| July 29, 2024 |
Exhibit 99.1 NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia — Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p<0.0001 ), which was sustained at day 36 |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Com |
|
| July 18, 2024 |
Exhibit 99.1 NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors Naarden, the Netherlands and Miami, USA; July 18, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD |
|
| July 9, 2024 |
NEWAMSTERDAM PHARMA COMPANY N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands NEWAMSTERDAM PHARMA COMPANY N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands July 9, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jason Drory Re: NewAmsterdam Pharma Company N.V. Registration Statement on Form S-3 Filed July 3, 2024 File No. 333-280687 Ladies and Gentlemen: Pursuant to Rule 461 under the Secu |
|
| July 3, 2024 |
As filed with the Securities and Exchange Commission on July 3, 2024 As filed with the Securities and Exchange Commission on July 3, 2024 Registration No. |
|
| July 3, 2024 |
As filed with the Securities and Exchange Commission on July 3, 2024 Table of Contents As filed with the Securities and Exchange Commission on July 3, 2024 Registration No. |
|
| July 3, 2024 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NewAmsterdam Pharma Company N. |
|
| July 3, 2024 |
Exhibit 4.2 NEWAMSTERDAM PHARMA COMPANY N.V. AS ISSUER, AND [], AS TRUSTEE, SUBORDINATED INDENTURE DATED AS OF [, ] SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE Reconciliation and tie between the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the Indenture dated as of [], []. SECTION OF Trust Indenture Act SECTION OF INDENTURE 310(a)(1) and (2) 7.09 310(a)(3) and (4 |
|
| July 3, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) NewAmsterdam Pharma Company N. |
|
| July 3, 2024 |
NewAmsterdam Pharma Company N.V. Inducement Plan. Exhibit 99.2 INDUCEMENT PLAN NEWAMSTERDAM PHARMA COMPANY N.V. INTRODUCTION Article 1 1.1 This document sets out the Company’s inducement plan for prospective Employees who qualify as Eligible Participants. This Plan applies in addition, and without prejudice, to the Company’s long-term incentive plan, the Company’s supplementary long-term incentive plan and the Company’s roll-over option plan; the |
|
| July 3, 2024 |
Exhibit 4.1 NEWAMSTERDAM PHARMA COMPANY N.V. AS ISSUER, AND [], AS TRUSTEE, SENIOR INDENTURE DATED AS OF [, ] SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE Reconciliation and tie between the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the Indenture dated as of [], []. SECTION OF Trust Indenture Act SECTION OF INDENTURE 310(a)(1) and (2) 7.09 310(a)(3) and (4) Not applic |
|
| July 3, 2024 |
NewAmsterdam Pharma Company N.V. Long-Term Incentive Plan. Exhibit 99.1 LONG-TERM INCENTIVE PLAN NEWAMSTERDAM PHARMA COMPANY N.V. INTRODUCTION Article 1 1.1 This document sets out the Company’s long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants. 1.2 The main purposes of this Plan are: a. to attract, retain and motivate Participants with the qualities, skills and experience needed to support an |
|
| June 11, 2024 |
Exhibit 99.1 NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office — New patent extends patent term for obicetrapib until July 2043 – Naarden, the Netherlands and Miami, USA; June 11, 2024 — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical co |
|
| June 11, 2024 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Com |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Comm |
|
| May 9, 2024 |
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT- - On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 - - Dosed first patients in TANDEM, pivotal Phase 3 trial evaluating fixed-dose combination of obicetrapib and ezetimibe; topline data expected in 1Q 2025 - - Company to host R&D event on May 16, 2024, beginning at 9:00 a. |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as Specified in Its Charter) The Netherlands 001-41562 N/A (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41562 NewAmsterdam Pharma Company N. |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| April 19, 2024 |
Up to $150,000,000 Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-275932 PROSPECTUS Up to $150,000,000 Ordinary Shares We have previously entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC (“TD Cowen”), dated December 7, 2023, relating to the sale of our ordinary shares, nominal value of €0.12 per share (the “Ordinary Shares”), offered b |
|
| April 12, 2024 |
Power of Attorney (included on the signature page hereto). Table of Contents As filed with the Securities and Exchange Commission on April 12, 2024 Registration No. |
|
| April 12, 2024 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No. 1 to Form F-3 on Form S-3 (Form Type) NewAmsterdam Pharma Company N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount |
|
| April 1, 2024 |
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer Exhibit 99.1 NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer NAARDEN, the Netherlands and MIAMI, April 1, 2024 — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-d |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Co |
|
| March 12, 2024 |
64,017,688 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS 64,017,688 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares This prospectus relates to the issuance by us of up to 1,736,545 ordinary shares, with a nominal value of € 0.12 per share (“Ordinary Shares”) underlying options issued pursuant to our Rollover Option Plan (such options, |
|
| March 4, 2024 |
Exhibit 99.1 ! ##$%&%’()*+,-.%/0&%&(121.’(%-2))(’13’(%1.141&2(’55&01’%&))6’01-&%’).3.121.’(’52(’55&01’74*62(* %&340.1.&%6(’0%-2))1-&0&7&2(*%2)&’5%&340.1.&%.(2(*%121&%’0840.%9.31.’(%.( :-.3-%43-’55&06%’).3.121.’(’0%2)& :’4)97&4()2 :54)+ ;< =>?<<@ABCDDAD E&012.(%121& F&(1%.(3)49&9.(1-.%/0&%&(121.’(1-2120&(’1-.%1’0.32)5231%20&5’0 :209G)’’H.(I%121& F&(1%5’0J40J’%&%’51-&%25&-207’0J0’K.%.’(%4(9&01-& L(. |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (Com |
|
| March 1, 2024 |
NAMS / NewAmsterdam Pharma Company N.V. / BCLS II Investco, LP - SC 13D/A Activist Investment SC 13D/A 1 d788549dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2) NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, nomina |
|
| March 1, 2024 |
EX-99.F 2 d788549dex99f.htm EX-99.F Exhibit F Lock-up Agreement February , 2024 Jefferies LLC Leerink Partners LLC As Representatives of the Several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 and c/o Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 RE: NewAmsterdam Pharma Company N.V. (the “Company”) Ladies & Gentlemen: The under |
|
| February 28, 2024 |
Exhibit 4.4 DESCRIPTION OF OUR SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and warrants to purchase ordinary shares of NewAmsterdam Pharma Company N.V. (the “Company,” “we,” “us,” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also includes a description of the ma |
|
| February 28, 2024 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No. 3 to Form F-1 on Form S-3 (Form Type) NewAmsterdam Pharma Company N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum |
|
| February 28, 2024 |
Mr. Mayur (Ian) Somaiya [***] [***] Dear Ian: On behalf of NewAmsterdam Pharma Corporation, I am pleased to offer you (“you” or “Executive”) employment with the Company as its Chief Financial Officer. NewAmsterdam Pharma Corporation (the “U.S. Subsidiary”) is an indirect wholly owned subsidiary of NewAmsterdam Pharma Company N.V. (“Parent”). The U.S. Subsidiary, Parent, and their respective subsid |
|
| February 28, 2024 |
Form of Option Award Agreement 1 AWARD AGREEMENT THIS AGREEMENT IS BETWEEN 1. NewAmsterdam Pharma Company N.V., a public company with limited liability, having its corporate seat in Naarden (address: Gooimeer 2-35, 1411 DC Naarden, trade register number: 86649051) (the “Company”); and 2. [name] (the “Participant”). NOW HEREBY AGREE AS FOLLOWS 1.1 Capitalised terms used herein have the meanings ascribed thereto in the Company’s |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
Michael Davidson [***] [***] Dear Michael: On behalf of NewAmsterdam Pharma Corporation, I am pleased to present you (“you” or “Executive”) this updated letter regarding your employment with the Company. |
|
| February 28, 2024 |
Employment Agreement, dated November 18, 2022, between NewAmsterdam Pharma B.V. and John Kastelein. Execution copy EMPLOYMENT AGREEMENT 1. NewAmsterdam Pharma B.V., a company with limited liability organ-ised under the laws of the Netherlands, having its corporate seat at Naarden, registered with the Chamber of Commerce under number 76133141, hereinafter referred to as the "Employer"; and 2. Mr Prof. J.J.P. (John) Kastelein, residing at [***], hereinafter referred to as the "Employee". The Emplo |
|
| February 28, 2024 |
EX-99.1 Exhibit 99.1 NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update — On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 — — Plan to initiate TANDEM, pivotal Phase 3 trial evaluating obicetrapib and ezetimibe fixed-dose combination, in 1Q 2024; topline data expected in 1Q 2025 — — |
|
| February 28, 2024 |
NewAmsterdam Pharma Company N.V. Long-term Incentive Plan. 1 LONG-TERM INCENTIVE PLAN NEWAMSTERDAM PHARMA COMPANY N.V. INTRODUCTION Article 1 1.1 This document sets out the Company's long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants. 1.2 The main purposes of this Plan are: a. to attract, retain and motivate Participants with the qualities, skills and experience needed to support and promote t |
|
| February 28, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation of NewAmsterdam Pharma Company N.V. NewAmsterdam Pharma Company N.V. Compensation Clawback Policy Adopted 18 July 2023 Purpose The Board of Directors (the “Board,” and each member, a “Director”) of NewAmsterdam Pharma Company N.V. (the “Company”) has adopted this compensation clawback policy (the “Policy”) which provides for (i) the recoupment of Incentive-Based Compensation in the event of an Accounting Restatement and (ii) the rec |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41562 NewAmsterdam Pharma Company N. |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) |
|
| February 21, 2024 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACt of 1934 (Amendment No. 3)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares (Title of Class of Securities) N62509 109 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Numb |
|
| February 15, 2024 |
Exhibit 99.1 NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants Naarden, the Netherlands and Miami, USA; February 13, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with |
|
| February 15, 2024 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) |
|
| February 15, 2024 |
Exhibit 4.1 Form of Pre-Funded Warrant NEWAMSTERDAM PHARMA COMPANY N.V. WARRANT TO PURCHASE ORDINARY SHARES Number of Ordinary Shares: [] (subject to adjustment) Warrant No. [] Date of Issuance: February [], 2024 (such date, the “Original Issue Date”) NewAmsterdam Pharma Company N.V., a Dutch public limited liability company (the “Company”), hereby certifies that, for good and valuable considerati |
|
| February 15, 2024 |
Exhibit 1.1 NewAmsterdam Pharma Company N.V. 4,488,159 Ordinary Shares (Nominal Value €0.12 Per Share) And Pre-Funded Warrants to Purchase 4,736,841 Ordinary Shares UNDERWRITING AGREEMENT February 13, 2024 JEFFERIES LLC LEERINK PARTNERS LLC PIPER SANDLER & CO. RBC CAPITAL MARKETS, LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o L |
|
| February 15, 2024 |
Exhibit 99.2 NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Naarden, the Netherlands and Miami, USA; February 13, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular dis |
|
| February 15, 2024 |
4,488,159 Ordinary Shares Pre-funded warrants to Purchase 4,736,841 Ordinary Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275932 PROSPECTUS SUPPLEMENT (To Prospectus dated December 19, 2023) 4,488,159 Ordinary Shares Pre-funded warrants to Purchase 4,736,841 Ordinary Shares We are offering 4,488,159 ordinary shares, with a nominal value of €0.12 per share (the “Ordinary Shares”) and, in lieu of Ordinary Shares to certain investors, pre-fund |
|
| February 14, 2024 |
NAMS / NewAmsterdam Pharma Company N.V. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2402141413ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary shares, nominal value €0.12 per sha |
|
| February 14, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm246065d23ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| February 14, 2024 |
NAMS / NewAmsterdam Pharma Company N.V. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d23sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* NEWAMSTERDAM PHARMA COMPANY N.V. (Name of Issuer) Ordinary Shares, Nominal value €0.12 per share (Title of Class of Securities) N62509 109 (CUSIP Number) December 31. 2023 (Date of Event Which Requires Filing o |
|
| February 13, 2024 |
Ordinary Shares Pre-funded warrants to Purchase Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275932 This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended, and the information in this preliminary prospectus supplement is not complete and may be changed. This pre |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) ( |
|
| January 22, 2024 |
EX-99.1 Exhibit 99.1 January 2024 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (C |
|
| January 8, 2024 |
EX-99.2 Exhibit 99.2 January 2024 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation |
|
| January 8, 2024 |
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors EX-99.1 Exhibit 99.1 NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors Naarden, the Netherlands and Miami, USA; January 8, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with res |
|
| January 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-41562 N/A (State or other jurisdiction of incorporation) (C |
|
| January 4, 2024 |
Exhibit 99.1 NewAmsterdam Pharma Announces 2024 Strategic Priorities — Positioned for three Phase 3 trial readouts over the next 18 months — — Topline data expected from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and BROADWAY trial in ASCVD in 4Q 2024 — — Plan to initiate TANDEM, a pivotal Phase 3 trial evaluating obicetrapib and ezetimibe fixed-dose combination, in 1Q 2024; topline data expected i |
|
| December 19, 2023 |
Up to $150,000,000 Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-275932 PROSPECTUS Up to $150,000,000 Ordinary Shares We have entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), dated December 7, 2023, relating to the sale of our ordinary shares, nominal value of €0.12 per share (the “Ordinary Shares”), offered by this prospectus. In accordance with the terms of t |
|
| December 15, 2023 |
NewAmsterdam Pharma Company N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands NewAmsterdam Pharma Company N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands December 15, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3561 Attn: Jason Drory Re: NewAmsterdam Pharma Company N.V. Registration Statement on Form F-3 Filed December 7, 2023 File No. 333-275932 Ladies and Gentlemen: Pursuant to Rule 461 und |
|
| December 7, 2023 |
Exhibit 1.2 NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES SALES AGREEMENT December 7, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: NewAmsterdam Pharma Company N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company |
|
| December 7, 2023 |
Exhibit 4.1 NEWAMSTERDAM PHARMA COMPANY N.V. AS ISSUER, AND [], AS TRUSTEE, SENIOR INDENTURE DATED AS OF [, ] SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE Reconciliation and tie between the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the Indenture dated as of [], []. SECTION OF Trust Indenture Act SECTION OF INDENTURE 310(a)(1) and (2) 7.09 310(a)(3) and (4) Not applic |
|
| December 7, 2023 |
As filed with the Securities and Exchange Commission on December 7, 2023 Table of Contents As filed with the Securities and Exchange Commission on December 7, 2023 Registration No. |
|
| December 7, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) NewAmsterdam Pharma Company N. |
|
| December 7, 2023 |
Exhibit 4.2 NEWAMSTERDAM PHARMA COMPANY N.V. AS ISSUER, AND [], AS TRUSTEE, SUBORDINATED INDENTURE DATED AS OF [, ] SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE Reconciliation and tie between the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the Indenture dated as of [], []. SECTION OF Trust Indenture Act SECTION OF INDENTURE 310(a)(1) and (2) 7.09 310(a)(3) and (4 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of |
|
| November 13, 2023 |
Exhibit 99.1 NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights — BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2H 2024 – — Announced initial data from Phase 2a clinical trial evaluating obicetrapib in patients with early Alzheimer’s Disease (“AD”) who carry an apolipoprotein E |
|
| November 13, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS SUPPLEMENT NO. 2 (to the Prospectus dated August 15, 2023) NewAmsterdam Pharma Company N.V. 64,347,070 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated August 15, 2023 (the “Prospec |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of |
|
| October 23, 2023 |
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer Exhibit 99.1 NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer Naarden, the Netherlands and Miami, USA; October 23, 2023 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address o |
|
| September 25, 2023 |
Exhibit 99.1 September 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sal |
|
| September 21, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS SUPPLEMENT NO. 1 (to the Prospectus dated August 15, 2023) NewAmsterdam Pharma Company N.V. 64,347,070 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated August 15, 2023 (the “Prospec |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address o |
|
| September 21, 2023 |
Exhibit 99.1 NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation – Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (“CSF”), respectively, indicating potential improvement of cholesterol metabolism in the brain – – Observed 8% increase in Aß42/ |
|
| September 20, 2023 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13G (including amendments thereto) jointly on behalf of each such party. D |
|
| September 20, 2023 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NEWAMSTERDAM PHARMA COMPANY N.V. (Name of Issuer) Ordinary Shares, nominal value EUR 0.12 per share (Title of Class of Securities) N62509109 (CUSIP Number) September 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of p |
|
| August 28, 2023 |
Exhibit 99.1 New Insights on CETP Inhibition from Genetic Research and Clinical Trials John J.P. Kastelein, MD PhD FESC Emeritus Professor of Medicine Department of Vascular Medicine Academic Medical Center (AMC) of the University of Amsterdam 1 Disclosures • Dr Kastelein reports consultancies with 89Bio, CiVi Biotech, CSL-Behring, Draupnir Bio, Menarini Ricerce, Madrigal, North Sea Therapeutics, |
|
| August 15, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS NewAmsterdam Pharma Company N.V. 64,347,070 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares This prospectus relates to the issuance by us of up to 1,736,545 ordinary shares, with a nominal value of € 0.12 per share (“Ordinary Shares”) underlying options issued pursuant to our Ro |
|
| August 15, 2023 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares (Title of Class of Securities) N62509 109 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Numb |
|
| August 14, 2023 |
EX-99.1 Exhibit 99.1 NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer Naarden, the Netherlands and Miami, USA; August 14, 2023 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high ris |
|
| August 14, 2023 |
EX-99.2 Exhibit 99.2 August 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation o |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of p |
|
| August 7, 2023 |
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements as at June 30, 2023 and for the six months ended June 30, 2023 and 2022 and the related notes to those financial statement |
|
| August 7, 2023 |
EX-99.1 Exhibit 99.1 NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights — Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median reduction in LDL-C (p<0.0001) — — Announced topline results from Phase 2b dose-finding trial evaluating obicetrapib in Jap |
|
| August 7, 2023 |
As filed with the Securities and Exchange Commission on August 7, 2023 Registration No. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of p |
|
| August 7, 2023 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) NewAmsterdam Pharma Company N. |
|
| August 7, 2023 |
CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS (UNAUDITED) Exhibit 99.1 CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS (UNAUDITED) For the six months ended June 30, Note 2023 2022 (In thousands of Euro, except per share amounts) Revenue 3 9,562 93,500 Research and development expenses 4 (72,873 ) (30,588 ) Selling, general and administrative expenses 5 (13,736 ) (9,294 ) Total operating expenses (86,609 ) (39,882 ) Operating (loss) / profit (77,047 ) |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of p |
|
| August 1, 2023 |
RA CAPITAL MANAGEMENT, L.P. - SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NEWAMSTERDAM PHARMA COMPANY N.V. (Name of Issuer) Ordinary Shares, Nominal value €0.12 per share (Title of Class of Securities) N62509 109 (CUSIP Number) June 8, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of pri |
|
| July 26, 2023 |
Exhibit 99.1 NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease — Exceeded Target Enrollment; Expect to Randomize More Than 2,500 Patients — — Topline Results Expected in 2H 2024 – Naarden, the Netherlands and Miami, USA; July |
|
| July 7, 2023 |
SC 13D/A CUSIP No. N62509 109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, Nominal value €0.12 per share (Title of Class of Securities) N62509 109 (CUSIP Number) Forbion Capital Partners Gooimeer 2-35 1411 DC Naarden The Netherlands |
|
| July 7, 2023 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each sh |
|
| July 7, 2023 |
EX-99.5 EXHIBIT 99.5 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each sh |
|
| July 7, 2023 |
EX-99.6 EXHIBIT 99.6 Lock-up Agreement June , 2023 Jefferies LLC SVB Securities LLC As Representatives of the Several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 and c/o SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 RE: NewAmsterdam Pharma Company N.V. (the “Company”) Ladies & Gentlemen: The undersigned is an officer and/or direc |
|
| July 7, 2023 |
Forbion Capital Fund IV Cooperatief U.A. - SC 13D SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. )* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, Nominal value €0.12 per share (Title of Class of Securities) N62509 109 (CUSIP Number) Forbion Capital Partners Gooimeer 2-35 1411 DC Naarden The Netherlands (Name, Address and Tele |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of pri |
|
| June 21, 2023 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS SUPPLEMENT NO. 4 (to the Prospectus dated April 24, 2023) NewAmsterdam Pharma Company N.V. 80,515,324 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 24, 2023 (the “Pro |
|
| June 20, 2023 |
VIKING GLOBAL INVESTORS LP - SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary shares, nominal value €0.12 per share (Title of Class of Securities) N62509109 (CUSIP |
|
| June 13, 2023 |
EX-99.E Exhibit E Lock-up Agreement June , 2023 Jefferies LLC SVB Securities LLC As Representatives of the Several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 and c/o SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 RE: NewAmsterdam Pharma Company N.V. (the “Company”) Ladies & Gentlemen: The undersigned is an officer and/or director |
|
| June 13, 2023 |
BCLS II Investco, LP - SC 13D/A SC 13D/A 1 d521028dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1) NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, nomina |
|
| June 12, 2023 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS SUPPLEMENT NO. 3 (to the Prospectus dated April 24, 2023) NewAmsterdam Pharma Company N.V. 80,515,324 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 24, 2023 (the “Pro |
|
| June 12, 2023 |
6-K 1 d510614d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Ne |
|
| June 12, 2023 |
Source: Cromwell WC, et al. Clin Lipidol. 2007 December 1; 1(6): 583–592 EX-99.1 Exhibit 99.1 Our Business Overview NewAmsterdam Pharma Company N.V. (“we,” “us,” “our” or the “Company”) is a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease (“CVD”) with residual elevation of low-density lipoprotein cholesterol (“LDL-C” or “LDL”), for whom existing therapies are not sufficiently effective o |
|
| June 12, 2023 |
Exhibit 1.1 Execution Version NewAmsterdam Pharma Company N.V. 13,857,415 Ordinary Shares (Nominal Value €0.12 Per Share) UNDERWRITING AGREEMENT June 6, 2023 JEFFERIES LLC SVB SECURITIES LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and G |
|
| June 9, 2023 |
Frazier Life Sciences X, L.P. - SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares (Title of Class of Securities) N62509 109 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Numb |
|
| June 8, 2023 |
NewAmsterdam Pharma Company N.V. 13,857,415 Ordinary Shares 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS SUPPLEMENT (to Prospectus dated April 24, 2023) NewAmsterdam Pharma Company N.V. 13,857,415 Ordinary Shares The selling securityholders named in this prospectus supplement (the “selling securityholders”), including entities affiliated with Forbion (such entities, collectively, “Forbion”), are offering a |
|
| June 6, 2023 |
NewAmsterdam Pharma Company N.V. 10,579,210 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are neither an offer to sell these securities nor a solicitation of an offer to buy these securities in any jurisdiction where the offer or sale is not perm |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of pri |
|
| June 5, 2023 |
EX-99.3 Exhibit 99.3 June 5, 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation |
|
| June 5, 2023 |
Exhibit 99.1 NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 — Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) — — 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55 |
|
| June 5, 2023 |
Exhibit 99.2 NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients — Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < 0.0001) in patients treated with 10mg obicetrapib— — 29.7% Median Reduction in Apo B and 37.0% Median Reduction in non-HDL-C from Baseline (p < 0.0001) in pati |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of prin |
|
| May 31, 2023 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of NewAmsterdam Pharma Company N.V. (the “Company”) to be held on June 20, 2023 at 4:00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the “AGM”). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board rep |
|
| May 23, 2023 |
Exhibit 99.1 NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023 — NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET — Naarden, the Netherlands and Miami, USA; May 23, 2023 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformat |
|
| May 23, 2023 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS SUPPLEMENT NO. 2 (to the Prospectus dated April 24, 2023) NewAmsterdam Pharma Company N.V. 80,515,324 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 24, 2023 (the “Pro |
|
| May 23, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of prin |
|
| May 8, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS SUPPLEMENT NO. 1 (to the Prospectus dated April 24, 2023) NewAmsterdam Pharma Company N.V. 80,515,324 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 24, 2023 (the “Prospectu |
|
| May 8, 2023 |
Exhibit 99.1 NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights — Completed enrollment in BROOKLYN Phase 3 clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (“HeFH”) ahead of schedule; topline results expected in 2H 2024 — — Announced positive topline results in January 2023 and scheduled to present full data |
|
| April 25, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 PROSPECTUS NewAmsterdam Pharma Company N.V. 80,515,324 Ordinary Shares 167,000 Private Placement Warrants to Purchase Ordinary Shares This prospectus relates to the issuance by us of up to 1,736,545 ordinary shares, with a nominal value of € 0.12 per share (“Ordinary Shares”) underlying options issued pursuant to our Ro |
|
| April 24, 2023 |
Exhibit 99.1 NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia — Enrollment Completed Several Months Ahead of Schedule, Reflecting Significant Unmet Need and Patient Demand for New Options — — Topline Results Expected in 2H 2024 – Naarden, the Netherlands and Miami, USA; April 24, 2 |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of pr |
|
| April 17, 2023 |
As filed with the Securities and Exchange Commission on April 17, 2023 POS AM Table of Contents As filed with the Securities and Exchange Commission on April 17, 2023 Registration No. |
|
| April 17, 2023 |
Calculation of Filing Fee Table. EX-FILING FEES 4 d482953dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) NewAmsterdam Pharma Company N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggreg |
|
| April 3, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Addr |
|
| April 3, 2023 |
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors Exhibit 99.1 NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors Naarden, the Netherlands and Miami, USA; April 3, 2023 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced the appointme |
|
| March 31, 2023 |
NewAmsterdam Pharma Company N.V. Long-Term Incentive Plan. EX-99.1 6 d481332dex991.htm EX-99.1 Exhibit 99.1 1 LONG-TERM INCENTIVE PLAN NEWAMSTERDAM PHARMA COMPANY N.V. INTRODUCTION Article 1 1.1 This document sets out the Company’s long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants. 1.2 The main purposes of this Plan are: a. to attract, retain and motivate Participants with the qualities, skil |
|
| March 31, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address o |
|
| March 31, 2023 |
Exhibit 2.4 DESCRIPTION OF OUR SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and warrants to purchase ordinary shares of NewAmsterdam Pharma Company N.V. (the “Company,” “we,” “us,” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also includes a description of the ma |
|
| March 31, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2023 S-8 As filed with the U.S. Securities and Exchange Commission on March 31, 2023 No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NewAmsterdam Pharma Company N.V. (Exact name of Registrant as specified in its charter) The Netherlands Not applicable (State or other jurisdiction of incorporation or organi |
|
| March 31, 2023 |
EX-99.1 Exhibit 99.1 NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update — Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected cash runway through 2026 — — Announced positive topline results from ROSE2 Phase 2 clini |
|
| March 31, 2023 |
Consent of Deloitte Accountant B.V., independent registered public accounting firm CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement (No. |
|
| March 31, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “E |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 31, 2023 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Davidson, M.D., certify that: 1. I have reviewed this annual report on Form 20-F of NewAmsterdam Pharma Company N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| March 31, 2023 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Louise Kooij, certify that: 1. I have reviewed this annual report on Form 20-F of NewAmsterdam Pharma Company N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or om |
|
| March 31, 2023 |
EX-13 5 nams-ex131.htm EX-13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securiti |
|
| March 31, 2023 |
NewAmsterdam Pharma Company N.V. Supplementary Long-Term Incentive Plan. Exhibit 99.2 SUPPLEMENTARY LONG-TERM INCENTIVE PLAN NEWAMSTERDAM PHARMA COMPANY N.V. INTRODUCTION Article 1 1.1 This document sets out the Company’s supplementary long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants. 1.2 The main purposes of this Plan are: a. to attract, retain and motivate Participants with the qualities, skills and exp |
|
| March 31, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) NewAmsterdam Pharma Company N. |
|
| March 7, 2023 |
Exhibit 99.1 March 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale wo |
|
| March 7, 2023 |
6-K 1 d449305d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The N |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact name of registrant as specified in its charter) Gooimeer 2-35 1411 DC Naarden The Netherlands (Address of pr |
